Xenetic Biosciences, Inc.
XBIO
$4.11
-$0.17-3.97%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.99% | 36.00% | 18.11% | 67.21% | -18.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.99% | 36.00% | 18.11% | 67.21% | -18.79% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 11.99% | 36.00% | 18.11% | 67.21% | -18.79% |
| SG&A Expenses | 64.23% | -1.37% | -12.72% | 9.32% | -41.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.20% | -14.76% | -20.52% | 41.12% | -36.32% |
| Operating Income | -34.14% | 46.72% | 43.32% | -9.05% | 45.84% |
| Income Before Tax | -34.99% | 49.46% | 45.08% | -16.76% | 45.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.99% | 49.46% | 45.08% | -16.76% | 45.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.99% | 49.46% | 45.08% | -16.76% | 45.94% |
| EBIT | -34.14% | 46.72% | 43.32% | -9.05% | 45.84% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 9.27% | 65.98% | 61.16% | -16.77% | 45.98% |
| Normalized Basic EPS | 9.24% | 65.98% | 61.16% | -16.78% | 45.99% |
| EPS Diluted | 9.27% | 65.98% | 61.16% | -16.77% | 45.98% |
| Normalized Diluted EPS | 9.24% | 65.98% | 61.16% | -16.78% | 45.99% |
| Average Basic Shares Outstanding | 48.78% | 48.57% | 41.36% | 0.03% | 0.08% |
| Average Diluted Shares Outstanding | 48.78% | 48.57% | 41.36% | 0.03% | 0.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |